EverGlade Insights Archives - EverGlade Consulting

EverGlade Insights

monoclonal antibody

BARDA Announces Solicitation to Improve Monoclonal Antibody Platforms for Pre-Exposure Prophylaxis

Leave a Comment / BARDA, EverGlade Insights / By

PrEP_Solicitation_Monoclonal_Antibody_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of monoclonal antibody (mAb) platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The solicitation focuses on advancing the development of mAb […]

BARDA Announces Solicitation to Improve Monoclonal Antibody Platforms for Pre-Exposure Prophylaxis Read More »

nucleic acid-based therapeutics

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis

Leave a Comment / BARDA, EverGlade Insights / By

PrEP_Solicitation_Nucleic_Acid_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of long-acting nucleic acid-based platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The specific goals of these PrEP DEV awards include

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis Read More »

cancer moonshot

Cancer Moonshot and the ARPA-H Cancer Funding Landscape

Leave a Comment / ARPA-H, EverGlade Insights / By

Even with incredible scientific progress, cancer remains the second highest leading cause of death in the United States (U.S.) and one of the highest causes of death worldwide. To accelerate and bolster the great innovations made in therapeutics, diagnostics, and patient care, the Biden-Harris administration has reignited the Cancer Moonshot initiative. This program, introduced by

Cancer Moonshot and the ARPA-H Cancer Funding Landscape Read More »

cell therapies

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT)

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

DECIDE_ET_Solicitation_DRAFT The Advanced Research Projects Agency for Health (ARPA-H) has introduced the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ET), representing a crucial initiative designed to revolutionize the production and validation of autologous cell therapies. This ET targets significant enhancements in the production processes at Academic Medical Centers (AMCs), focusing on

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT) Read More »

Senior chemist analysing blood sample while working overtime in chemistry equipped laboratory.

ARPA-H Announces Proposers’ Day for New POSEIDON Program

Leave a Comment / ARPA-H, EverGlade Insights / By

Proposers’ Day Notice 24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has recently unveiled an exciting initiative named POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in ONcology). This program aims to drastically shift the current landscape of cancer detection through innovative, synthetic biology-based approaches. As part of this groundbreaking venture, ARPA-H is

ARPA-H Announces Proposers’ Day for New POSEIDON Program Read More »

African American woman in a technically advanced career

ARPA-H Announces Small Business Opportunities

Leave a Comment / ARPA-H, EverGlade Insights / By

The Advanced Research Projects Agency for Health (ARPA-H) has announced an upcoming solicitation for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) contracts for FY2024. The initiative targets innovative firms capable of conducting cutting-edge research and development, with a focus on commercializing the results. The solicitation includes opportunities for Phase I, Direct to Phase II, and Fast Track contracts.

ARPA-H Announces Small Business Opportunities Read More »

Abstract virus on blue background

BARDA Announces Request for Project Proposal to Establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services

Leave a Comment / BARDA, EverGlade Insights / By

Biomedical Advanced Research and Development Authority (BARDA) through the Rapid Response Partnership Vehicle (RRPV) initiative released a Request for Project Proposals (RPP) to establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services to support vaccine development and response to pandemics and emerging infectious diseases.

BARDA Announces Request for Project Proposal to Establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services Read More »

Medical Countermeasures through BARDA

BARDA Announces Request for Project Proposal for On-Demand Manufacturing

Leave a Comment / BARDA, EverGlade Insights / By

The Biomedical Advanced Research and Development Authority (BARDA) is spearheading this effort with its innovative On-Demand Manufacturing program. This initiative is designed to revolutionize the production and distribution of MCMs by developing portable, continuous, and end-to-end manufacturing systems.

BARDA Announces Request for Project Proposal for On-Demand Manufacturing Read More »

Scroll to Top